Sino Biopharmaceutical

Update in progress

1177.HK (HKSE)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Sino Biopharmaceutical Limited is an investment holding company that operates as an R&D pharmaceutical conglomerate in China. It runs three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The group develops and markets oncology, liver disease, respiratory, and surgery/analgesia medicines under multiple brands, and pursues long‑term investments and healthcare ventures. Established 2000, it is headquartered in Wan Chai, Hong Kong.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.14; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.22; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive